It ought to correct overbought Nasdaq Biotechnology Index: The Nasdaq Biotech index has grown about 50 percent since Yellen's valuation comments. Superarando por mucho el desempeño de los indices composite y S&P500, this boom is due primarily to the pharmaceutical companies who have monopolized the attention of investors the past few months, beyond the debate of whether exist a bubble formation the Nasdaq Biotechnology Index It ought to correct their overbought at least 6% as it has done in later months
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.